Kro­nos Bio ax­es near­ly one-fifth of staff to pre­serve cash for two can­cer pro­grams

Kro­nos Bio is down­siz­ing its work­force by 19% as part of broad­er re­struc­tur­ing ef­forts meant to save cash, so that the com­pa­ny can con­tin­ue work on its pro­grams in sol­id tu­mors and acute myeloid leukemia.

The US biotech plans to re­duce its staff in a bid to ex­tend its cash run­way through 2026. As of Jan. 1, Kro­nos Bio had 97 full-time em­ploy­ees, ac­cord­ing to an SEC fil­ing. In ad­di­tion to ad­vanc­ing its clin­i­cal-stage pro­grams, the com­pa­ny said it will al­so fo­cus its dis­cov­ery-stage work on “ma­tur­ing projects” and its part­ner­ship ac­tiv­i­ties with Genen­tech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER